Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2022-06-16 Earnings Release
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Final Results
Earnings Release Classification · 95% confidence The document is an 'Earnings Release' (ER). It is titled 'Final Results for the Year Ended 31 March 2022' and provides a summary of financial performance, including NAV, portfolio valuation, and capital deployment. While it contains financial data, it is structured as a press release announcement (RNS Number 0602P) rather than the full, comprehensive Annual Report (10-K) document. It highlights key performance indicators and management commentary, fitting the definition of an Earnings Release. FY 2022
2022-06-16 English
Autolus presents clinical data updates at EHA
Regulatory Filings Classification · 95% confidence The document is an RNS announcement from Syncona Limited, dated June 10, 2022, reporting on clinical data updates presented by its portfolio company, Autolus Therapeutics Plc, at the EHA Congress. The text primarily summarizes scientific and clinical trial results (safety, efficacy, response rates) for various drug candidates (AUTO4, AUTO1/22, obe-cel). This content is typical of a press release or a general regulatory update concerning scientific progress, rather than a formal financial report (like 10-K or IR) or a specific management/governance filing. Since it is a general announcement of corporate/scientific news released via the RNS system, and it doesn't fit the specific categories like ER (Earnings Release), IP (Investor Presentation), or MDA (Management Discussion), the most appropriate general classification for a non-financial, non-governance regulatory update is Regulatory Filings (RNS). The document is not merely announcing the publication of a report but is the content of the announcement itself.
2022-06-10 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified by the header 'RNS Number' and contains the standard formatting for a regulatory notification disseminated via RNS (Regulatory News Service). Specifically, the form title is 'TR-1: Standard form for notification of major holdings', which details changes in voting rights by a shareholder (Waverton Investment Management Limited) crossing a notification threshold. This type of filing reports changes in significant share ownership, which corresponds directly to the definition for Major Shareholding Notification (MRQ). Although RNS is mentioned, the content is a specific regulatory disclosure, making MRQ the most precise classification over the general RNS fallback.
2022-06-08 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is very short (2863 characters) and explicitly states that the company 'will announce its final results for the year ended 31 March 2022 on Thursday 16 June 2022.' It does not contain the results themselves, but rather announces the future publication date of those results and provides details for an associated webcast/conference call. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report falls under Report Publication Announcement (RPA).
2022-05-19 English
Syncona invests in $56 million SwanBio Series B
Share Issue/Capital Change Classification · 99% confidence The document is identified by the 'RNS Number' header and contains a date (18 May 2022) and company name (Syncona Limited). The content describes a specific corporate action: an investment in a Series B financing round for another company (SwanBio Therapeutics). This type of announcement, detailing financing, investment stakes, and clinical development updates, is characteristic of a regulatory news service release in the UK market. Since it is a specific announcement of a corporate event (financing/investment) that doesn't fit perfectly into the defined categories like 10-K, ER, or CAP (which usually implies a formal offering or capital structure change rather than a portfolio investment update), and it is clearly distributed via RNS, the most appropriate classification is the general regulatory announcement category, RNS, as per the definition: 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories.' It is not a short announcement pointing to a larger report, as the full details of the investment are present.
2022-05-18 English
Autolus to present clinical data at EHA Congress
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from Syncona Limited, dated May 12, 2022. The core content is Syncona noting that its portfolio company, Autolus Therapeutics Plc, will present clinical data updates at the EHA Congress and that a copy of Autolus's announcement is set out below. The text includes detailed scientific abstracts (AUTO4, AUTO1/22, AUTO1) and announces a subsequent conference call to discuss the data. This structure—an announcement by a holding company referencing a portfolio company's upcoming presentation of scientific/clinical data, followed by the full text of the underlying announcement—is characteristic of a general regulatory update or news release. Since the document is primarily relaying information about scientific data presentations and an upcoming call, and it is not the full financial report (10-K), the interim report (IR), the earnings release (ER), or the presentation itself (IP), it fits best as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were only announcing the abstracts. Given the length and the inclusion of the full details of the underlying press release, RNS is the most appropriate general category for this type of corporate news dissemination that doesn't fit a more specific financial or governance code.
2022-05-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.